Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Therion Biologics completes financing, accelerates therapeutic vaccine programs

July 9, 1999

Cell Genesys completes phase I/II GVAX trial and earns milestone payment

July 6, 1999

IL-4 fusion toxin effective in preclinical Kaposi's sarcoma models

July 2, 1999

Avax to launch M-Vax in Australia, forms joint venture for AC Vaccine

July 2, 1999

Transgene initiates phase I trial of malignant melanoma product

June 25, 1999

ImmunoGen receives second milestone payment for anticancer prodrug from SmithKline Beecham

June 22, 1999

Corixa teams up with Japan Tobacco on lung cancer vaccine research

June 21, 1999

Seven preclinical studies demonstrate antitumor activity of NovoMAb-G2

June 16, 1999

Campath-1H trial results presented in Barcelona

June 15, 1999

Follow-up data presented for Bexxar cancer therapy

June 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...